Risk Minimisation Materials

Bavencio 20 mg/ml concentrate for solution for infusion (avelumab) – Healthcare Professional FAQ

Healthcare Professional FAQ

For Healthcare Professionals

Bavencio 20 mg/ml concentrate for solution for infusion (avelumab) – Patient Alert Card

Patient Alert Card

Bavencio 20 mg/ml concentrate for solution for infusion (avelumab) – Patient Information Brochure

Patient Information Brochure

Benepali ® (etanercept): Brief training on additional Risk Minimisation Measures_v9.0_22Jan16 (UK/IE)

Developed to educate healthcare professionals that benepali is not for paediatric use and to prevent or reduce medication errors for pre-filled pen and pre-filled syringe.

For Healthcare Professionals

Benepali Patient Alert Card

The PAC is located inside the Benepali box and should be carried by patients during treatment and for 2 months after the last dose. The PAC contains the following key elements for patients treated with Benepali: • The risk of opportunistic infections and tuberculosis (TB) • The risk of Congestive Heart Failure (CHF). • Benepali is not for use in children

Benepali Quick Reference Guide for Pre-filled Pen (PFPen EN v1.1)

Developed as a teaching guide for healthcare professionals to facilitate training of the patients in the safe use of the pre-filled pen.

For Healthcare Professionals

Benepali Quick Reference Guide for Pre-filled Syringe (PFSyringe EN v1.1)

Provides a teaching guide for healthcare professionals to facilitate training of the patients in the safe use of the pre-filled syringes

For Healthcare Professionals

Bivaluridin Accord dosing and administration instruction for medically managed ACS patients with urgent or early intervention

This document will serve as a guide to HCP on dosing and administration of Bivaluridin Accord for medically managed ACS patients with urgent or early intervention.

For Healthcare Professionals

Bivaluridin Accord dosing and administration instruction for PCI and Primary PCI

This document will provide instruction for dosing and administration of Bivaluridin Accord following PCI and primary PCI

For Healthcare Professionals

Direct Healthcare Professional Communication on approved dosing regimens for Accord Bivalirudin for Percutaneous Coronary Intervention (PCI), following reports of inappropriate use

This letter will provide guidance on the dosing regimen, administration instructions, safety concerns and suspected adverse reactions to HCPs for patients undergoing Percutaneous Coronary Intervention (PCI).

For Healthcare Professionals

BLINCYTO Guide for Nurses

This educational brochure contains important information regarding the administration of BLINCYTO and the risks of medication errors and neurologic events. This educational material is essential to ensure the safe and effective use of the product and appropriate management of the important selected risks and therefore it is advised to be read carefully before administering the medicinal product.To request a copy of the brochure, please contact Amgen Medical Information on +44 (0) 1223 436441

For Healthcare Professionals

BLINCYTO Guide for Patients and Caregivers

This educational brochure contains important information you should know before receiving BLINCYTO. This educational material is essential to ensure the safe and effective use of the drug and appropriate management of the important selected risks. Please read it carefully before taking the medicinal product. To request a copy of this guide, please contact Amgen Medical Information on +44 (0) 1223 436441

BLINCYTO Guide for Pharmacists

This educational brochure contains important information regarding the reconstitution and preparation procedures for blinatumomab. To ensure the safe and effective use of the medicinal product and appropriate management of the important selected risks, please carefully read this material before reconstituting and preparing of the medicinal product.To request a copy of the brochure, please contact Amgen Medical Information on +44 (0) 1223 436441

For Healthcare Professionals

BLINCYTO Guide for Physicians

This educational brochure contains important information regarding the administration of BLINCYTO and the risks of medication errors and neurologic events. This educational material is essential to ensure the safe and effective use of the product and appropriate management of the important selected risks and therefore it is advised to be read carefully before prescribing and administering the medicinal product.To request a copy of the brochure, please contact Amgen Medical Information on +44 (0) 1223 436441

For Healthcare Professionals

BLINCYTO Patient Alert Card

This BLINCYTO patient alert card contains a warning message for HCPs that the patient is using BLINCYTO, includes contact details of the BLINCYTO prescriber and treatment start date, and information on the importance of reporting ADRs. To request a copy of the patient card, please contact Amgen Medical Information on +44 (0) 1223 436441

Bosentan Accord - Important Safety Information for Prescribers

This guide includes important safety information which must be considered before a patient is prescribed Bosentan Accord.

For Healthcare Professionals

Bosentan Patient Alert Card

Important Safety Alerts for Patients taking Bosentan Accord (bosentan)

Bosentan- HCP Presciber Guide

For hard copies please contact our medical information department on 0800 090 2408 or email UKMedInfo@zentiva.com .

For Healthcare Professionals

Bosentan- Patient Alert Guide

For hard copies please contact our medical information department on 0800 090 2408 or email UKMedInfo@zentiva.com

Bosentan Mylan - Important Safety Information for Prescribers

This guide includes important safety information which must be considered before a patient is prescribed Bosentan Mylan.

For Healthcare Professionals

Bosentan Patient Alert Card

Important Safety Alerts for Patients taking Bosentan Mylan (bosentan)

Risk Minimisation Information on Potential Risk of Medication Errors - Guide for HCPs

This educational guide is provided to highlight and minimise the potential risk of prescribing and administration errors (medication errors) due to the differences between Braltus (tiotropium bromide) and the originator product Spiriva® HandiHaler® (tiotropium bromide) with respect to the pre-metered dose.

For Healthcare Professionals

Brancico XL 50mg, 150mg, 200mg, 300mg and 400mg prolonged-release tablets Educational material for health care professionals

Educational material for health care professionals Brancico XL 50mg, 150mg, 200mg, 300mg and 400mg prolonged-release tablets For hard copies please contact our medical information department at 0800 090 2408 or email UKMedInfo@zentiva.com

For Healthcare Professionals

Appropriate use of Brinavess - Healthcare Professional Card

Appropriate use of Brinavess - Healthcare Professional Card Brinavess 20 mg/ml concentrate for solution for infusion (vernakalant hydrochloride)

For Healthcare Professionals

Bronchitol Healthcare Professional Leaflet

Bronchitol Healthcare Professional Leaflet

For Healthcare Professionals